- Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The acquisition is expected to finalize in Q1’21
- The acquisition will expand Takeda’s I-O portfolio with the addition of two development candidates (MVC-101 & MVC-280) and Maverick’s T-cell engagers COBRA platform, specifically designed to target solid tumor
- The acquisition 2017 collaboration of the companies to develop conditionally active T-cell engager therapies, in which Takeda received an equity stake and an exclusive right to acquire Maverick after 5yrs.
Click here to read full press release/ article | Ref: Takeda | Image: Maverick